STOCK TITAN
  1. Home
  2. Sec-filings
  3. NEO
  4. [8-K] NEOGENOMICS INC Reports Material Event

NeoGenomics (NEO) General Counsel Alicia Olivo set to depart in September 2026

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

NeoGenomics, Inc. reported that Alicia Olivo, Executive Vice President, General Counsel & Business Development, will transition from her role and cease to serve as General Counsel effective September 21, 2026. She will remain an employee through October 2, 2026 for transitional purposes.

The company states that, in connection with her departure, Ms. Olivo will be eligible to receive separation payments and benefits in line with Section 5(b) of her employment agreement, which had been filed previously as part of NeoGenomics’ Form 10-K for the year ended December 31, 2025.

Positive

  • None.

Negative

  • None.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
General Counsel role end date September 21, 2026 Effective date when Alicia Olivo ceases to serve as General Counsel
Employment end date October 2, 2026 Date through which Alicia Olivo remains an employee for transitional purposes
Announcement date August 11, 2026 Date NeoGenomics announced Alicia Olivo’s transition and departure details
separation payments financial
"Ms. Olivo will be eligible to receive separation payments and benefits"
employment agreement regulatory
"consistent with the terms of Section 5(b) of Ms. Olivo’s employment agreement"
emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

FAQ

What executive change did NeoGenomics (NEO) disclose on August 11, 2026?
NeoGenomics disclosed that Alicia Olivo, EVP, General Counsel & Business Development, will transition from her role and cease serving as General Counsel effective September 21, 2026, while remaining an employee for transition support until October 2, 2026.

When will NeoGenomics (NEO) General Counsel Alicia Olivo’s role end?
NeoGenomics stated that Alicia Olivo will cease to serve as General Counsel effective September 21, 2026. She will, however, remain employed by the company for transitional purposes until October 2, 2026.

Will NeoGenomics (NEO) provide severance or separation benefits to Alicia Olivo?
Yes. NeoGenomics indicated that Alicia Olivo will be eligible for separation payments and benefits consistent with Section 5(b) of her employment agreement, which was previously incorporated by reference in the company’s Form 10-K for 2025.

What role did Alicia Olivo hold at NeoGenomics (NEO) before her transition?
Alicia Olivo served as EVP, General Counsel & Business Development at NeoGenomics. The company announced that she will transition from this role, with her General Counsel responsibilities ending on September 21, 2026 and employment ending on October 2, 2026.

Is there detail on the amount of separation payments for NeoGenomics (NEO) executive Alicia Olivo?
The company did not specify amounts in this disclosure. It stated that separation payments and benefits will follow Section 5(b) of Ms. Olivo’s employment agreement, a form that had been previously filed with the Form 10-K for 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →
0001077183FALSE00010771832026-08-072026-08-07

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549 
 
FORM 8-K  
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
August 7, 2026
 
NEOGENOMICS, INC.
(Exact name of registrant as specified in its charter) 
 
Nevada
001-35756
74-2897368
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification No.)

 
9490 NeoGenomics Way,Fort Myers,Florida33912
(Address of principal executive offices)(Zip Code)
(239) 768-0600
(Registrant’s telephone number, including area code) 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading SymbolName of each exchange on which registered
Common stock ($0.001 par value)NEOThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 



Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On August 11, 2026, NeoGenomics, Inc. (the “Company”) announced that Alicia Olivo, EVP, General Counsel & Business Development, would transition from her role with the Company and cease to serve as General Counsel effective as of September 21, 2026. Ms. Olivo will remain an employee of the Company until October 2, 2026 for transitional purposes. In connection with her departure from the Company, Ms. Olivo will be eligible to receive separation payments and benefits consistent with the terms of Section 5(b) of Ms. Olivo’s employment agreement, the form of which was incorporated by reference in the Company’s Form 10-K for the fiscal year ended December 31, 2025, as filed with the Securities and Exchange Commission on February 17, 2026.

Item 9.01
Financial Statements and Exhibits.

(a)
Not applicable
(b)
Not applicable
(c)
Not applicable
(d)
Exhibits.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
NEOGENOMICS, INC.
Date: August 11, 2026By:/s/ Abhishek Jain
Name:Abhishek Jain
Title:Chief Financial Officer


Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents

Other Documents